Literature DB >> 18183025

A quantitative analysis of kinase inhibitor selectivity.

Mazen W Karaman1, Sanna Herrgard, Daniel K Treiber, Paul Gallant, Corey E Atteridge, Brian T Campbell, Katrina W Chan, Pietro Ciceri, Mindy I Davis, Philip T Edeen, Raffaella Faraoni, Mark Floyd, Jeremy P Hunt, Daniel J Lockhart, Zdravko V Milanov, Michael J Morrison, Gabriel Pallares, Hitesh K Patel, Stephanie Pritchard, Lisa M Wodicka, Patrick P Zarrinkar.   

Abstract

Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome. We present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome. The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns. To enable a global analysis of the results, we introduce the concept of a selectivity score as a general tool to quantify and differentiate the observed interaction patterns. We further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18183025     DOI: 10.1038/nbt1358

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  842 in total

1.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authors:  Adam S Crystal; Alice T Shaw; Lecia V Sequist; Luc Friboulet; Matthew J Niederst; Elizabeth L Lockerman; Rosa L Frias; Justin F Gainor; Arnaud Amzallag; Patricia Greninger; Dana Lee; Anuj Kalsy; Maria Gomez-Caraballo; Leila Elamine; Emily Howe; Wooyoung Hur; Eugene Lifshits; Hayley E Robinson; Ryohei Katayama; Anthony C Faber; Mark M Awad; Sridhar Ramaswamy; Mari Mino-Kenudson; A John Iafrate; Cyril H Benes; Jeffrey A Engelman
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity.

Authors:  Babal Kant Jha; Irina Polyakova; Patricia Kessler; Beihua Dong; Benjamin Dickerman; Ganes C Sen; Robert H Silverman
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

3.  Targeting diverse signaling interaction sites allows the rapid generation of bivalent kinase inhibitors.

Authors:  Zachary B Hill; B Gayani K Perera; Simeon S Andrews; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2011-12-22       Impact factor: 5.100

4.  Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model.

Authors:  Sachiko Ohshima-Hosoyama; Monika A Davare; Suresh I Prajapati; Jinu Abraham; Sangeet Lal; Laura D Nelon; Aoife Kilcoyne; Francis J Giles; Martha A Hanes; Brian P Rubin; Charles Keller
Journal:  J Pediatr Hematol Oncol       Date:  2012-03       Impact factor: 1.289

5.  Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.

Authors:  Mingqiang Ren; Haiyan Qin; Ruizhe Ren; Josephine Tidwell; John K Cowell
Journal:  Cancer Res       Date:  2011-09-21       Impact factor: 12.701

Review 6.  Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.

Authors:  Rajesh Gupta; Michael L Maitland
Journal:  Curr Hypertens Rep       Date:  2011-12       Impact factor: 5.369

7.  Targeting Pim Kinases and DAPK3 to Control Hypertension.

Authors:  David A Carlson; Miriam R Singer; Cindy Sutherland; Clara Redondo; Leila T Alexander; Philip F Hughes; Stefan Knapp; Susan B Gurley; Matthew A Sparks; Justin A MacDonald; Timothy A J Haystead
Journal:  Cell Chem Biol       Date:  2018-07-19       Impact factor: 8.116

Review 8.  Janus kinases: an ideal target for the treatment of autoimmune diseases.

Authors:  Massimo Gadina
Journal:  J Investig Dermatol Symp Proc       Date:  2013-12

9.  Contribution of increased VEGF receptors to hypoxic changes in fetal ovine carotid artery contractile proteins.

Authors:  Olayemi O Adeoye; Stacy M Butler; Margaret C Hubbell; Andrew Semotiuk; James M Williams; William J Pearce
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

10.  Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.

Authors:  Szu-Yuan Pu; Fei Xiao; Stanford Schor; Elena Bekerman; Fabio Zanini; Rina Barouch-Bentov; Claude M Nagamine; Shirit Einav
Journal:  Antiviral Res       Date:  2018-05-16       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.